IgG4-related pleural effusion with high adenosine deaminase levels: A case report and literature review. 2021

Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
Respiratory Disease Center.

BACKGROUND Levels of pleural fluid adenosine deaminase (ADA), a useful marker for the diagnosis of tuberculous pleurisy, are elevated in some reports of immunoglobulin G4 (IgG4)-related pleural effusion. We describe a patient with IgG4-related pleural effusion who exhibited a high concentration of ADA. Furthermore, we reviewed the literature to compare patients with IgG4-related pleural effusion and tuberculous pleurisy. METHODS A 75-year-old male patient had dyspnea for 1 month with a left pleural effusion that was exudative, lymphocyte dominant. The pleural fluid test results revealed a total protein (TP) concentration of 6.60 g/dl, a lactate dehydrogenase (LDH) level of 383 IU/dl, and an ADA concentration of 54.5 U/L. An interferon gamma release assay showed a negative result. METHODS Histological analysis of the thoracoscopic pleural biopsy revealed lymphoplasmacytic infiltration, with 80 IgG4-positive plasma cells/high-power field, and an IgG4/IgG ratio of approximately 40% to 50%. Other diseases were ruled out based on symptoms, negative autoimmune antigen results, and histopathologic findings. Thus, he was diagnosed with IgG4-related pleural effusion. METHODS He received 15 mg of prednisolone as therapy. RESULTS His pleural effusion and symptoms improved gradually within several months, and prednisolone was tapered to 6 mg daily. CONCLUSIONS It is important to distinguish between IgG4-related pleural effusion and tuberculous pleurisy. Therefore, we compared 22 patients with IgG4-related pleural effusion from PubMed and the Japan Medical Abstracts Society to 40 patients with tuberculous pleurisy at Fukujuji Hospital from January 2017 to May 2019. According to thoracentesis findings, 14 of 18 patients with IgG4-related pleural effusion had high ADA more than 40 U/L. The pleural effusion of patients with IgG4-related pleural effusion showed higher TP levels (P < .001) and lower LDH (P < .001) and ADA levels (P = .002) than those with tuberculous pleurisy. Moreover, the pleural fluid ADA/TP ratio was a good predictor for differentiating IgG4-related pleural effusion and tuberculous pleurisy (area under the receiver operating characteristic curve of 0.909; 95% confidence level: 0.824-0.994).

UI MeSH Term Description Entries
D008297 Male Males
D010994 Pleura The thin serous membrane enveloping the lungs (LUNG) and lining the THORACIC CAVITY. Pleura consist of two layers, the inner visceral pleura lying next to the pulmonary parenchyma and the outer parietal pleura. Between the two layers is the PLEURAL CAVITY which contains a thin film of liquid. Parietal Pleura,Visceral Pleura,Pleura, Parietal,Pleura, Visceral
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004796 Clinical Enzyme Tests Analyses for a specific enzyme activity, or of the level of a specific enzyme that is used to assess health and disease risk, for early detection of disease or disease prediction, diagnosis, and change in disease status. Enzyme Tests, Clinical,Clinical Enzyme Test,Enzyme Test, Clinical,Test, Clinical Enzyme,Tests, Clinical Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077733 Immunoglobulin G4-Related Disease A spectrum of systemic autoimmune diseases in which IMMUNOGLOBULIN G4 plays a pathophysiologic role. It can affect multiple organs in highly variable presentations, characterized by inflammatory lesions composed of IgG4-positive PLASMA CELLS, further infiltrated by T helper cells (T-LYMPHOCYTES, HELPER-INDUCER) when linked to progressive FIBROSIS and eventual organ damage. IgG4-Related Kidney Disease,IgG4-Related Sclerosing Disease,Immunoglobulin G4-Related Kidney Disease,Immunoglobulin G4-Related Sclerosing Disease,IgG4 Related Systemic Disease,IgG4-Associated Autoimmune Disease,IgG4-RD,IgG4-Related Disease,Autoimmune Disease, IgG4-Associated,IgG4 Associated Autoimmune Disease,IgG4 Related Disease,IgG4 Related Kidney Disease,IgG4 Related Sclerosing Disease,IgG4-Associated Autoimmune Diseases,IgG4-Related Diseases,IgG4-Related Kidney Diseases,IgG4-Related Sclerosing Diseases,Immunoglobulin G4 Related Disease,Immunoglobulin G4 Related Kidney Disease,Immunoglobulin G4 Related Sclerosing Disease,Immunoglobulin G4-Related Diseases,Kidney Disease, IgG4-Related,Sclerosing Disease, IgG4-Related
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
January 2023, Annals of laboratory medicine,
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
January 2021, Open medicine (Warsaw, Poland),
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
August 2018, Internal medicine (Tokyo, Japan),
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
July 2022, Medicine,
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
February 2024, Respirology case reports,
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
January 2023, BMC geriatrics,
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
July 2021, Internal medicine (Tokyo, Japan),
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
June 2021, Medicina clinica,
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
October 2013, Cytopathology : official journal of the British Society for Clinical Cytology,
Masafumi Shimoda, and Yoshiaki Tanaka, and Kozo Morimoto, and Masao Okumura, and Kiyomi Shimoda, and Tamiko Takemura, and Teruaki Oka, and Takashi Yoshiyama, and Kozo Yoshimori, and Ken Ohta
October 1986, Chest,
Copied contents to your clipboard!